• HDL and the Dyslipidemia of Diabetes Examining the Increased Risk of Atherosclerotic Events in Type 2 Diabetes
  • CME

  • HDL & the Dyslipidemia of Diabetes: Examining the Increased Risk of Atherosclerotic Events in Type 2 Diabetes

  • Author(s)/Faculty: Robert H. Eckel, MD; Henry Ginsberg, MD; Theodore Mazzone, MD, FACP; Alan R. Tall, MD
    Source: Endocrine Today
    Type: Monograph Articles/Items: 3
    Release Date: 10/1/2011 Expiration Date: 10/31/2012
    Credit Type: CME Number of Credit(s): 1.25
    Cost: Free Provider: Vindico Medical Education
  • Diabetes significantly increases a patient’s risk of atherosclerotic events. In this monograph, leading clinicians will evaluate and explain how the implementation of therapeutic lifestyle changes, diet, and exercise along with appropriate medication can improve HDL levels and attenuate cardiovascular risk in the patient with type 2 diabetes. The safety and efficacy of treatment strategies for dyslipidemia concomitant to diabetes will be addressed, including CETP inhibition, an emerging approach that increases HDL concentration and may reduce atherosclerotic events.

Sponsorship Statement: This continuing education activity is jointly sponsored by Vindico Medical Education and Vindico Medical Education

Support Statement: There is no commercial support for this activity. The original release of this content was supported by an educational grant from Vindico Medical Education

Target Audience: The intended audience for the activities is endocrinologists, diabetologists, lipidologists, and other health care professionals involved in the treatment of patients with type 2 diabetes.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Implement diet, exercise, lifestyle changes, and medication to raise levels of HDL and offset the risk of cardiovascular disease in type 2 diabetes.
  • Explain how CETP inhibition increases HDL concentration and may act to reduce the residual risk of atherosclerotic events.
  • Evaluate clinical trial data for the safety and efficacy of emerging treatment options for dyslipidemia concomitant to diabetes.

Course Chair:
Robert H. Eckel, MD
Professor of Medicine
Division of Endocrinology, Metabolism & Diabetes
Division of Cardiology
Professor of Physiology & Biophysics
Charles A. Boettcher Endowed Chair in Atherosclerosis
University of Colorado
Anschutz Medical Campus
Aurora, CO

Faculty:
Henry Ginsberg, MD
Irving Professor of Medicine
Director of the Irving Institute for Clinical and Translational Research
Columbia University
New York, NY

Theodore Mazzone, MD, FACP
Professor, Departments of Medicine, Pharmacology, and Kinesiology and Human Nutrition
Chief, Section of Endocrinology, Diabetes and Metabolism
Director, Center for Clinical and Translational Research
University of Illinois at Chicago
Chicago, IL

Alan R. Tall, MD
Tilden Weger Bieler Professor of Medicine
Professor of Physiology & Cellular Biophysics
Columbia University
New York, NY

Accreditation:
This educational activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Endocrine Today® and Vindico Medical Education. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Vindico Medical Education designates this enduring material activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, October 2011 to October 31, 2012.

How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, read the articles, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)TM certificate.

Faculty:
Robert H. Eckel, MD
Henry Ginsberg, MD
Theodore Mazzone, MD, FACP
Alan R. Tall, MD

External Reviewer:
William James Howard, MD

Medical Writer:
Valerie Zimmerman, PhD

Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Planning Committee and Faculty members report the following relationship(s):
Robert H. Eckel, MD
Consulting Fees: Esperion; Genfit; GTC Nutrition; Johnson & Johnson; Pfizer
Contracted Research: Diadexus; GSK; Sanofi-aventis

Henry Ginsberg, MD
Consulting Fees: Abbott; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; ISIS; Merck & Co, Inc; Novartis; Pfizer; Regeneron; Sepracor; Solvay
Contracted Research: AstraZeneca; ISIS; Merck & Co, Inc; Roche

Theodore Mazzone, MD, FACP
Consulting Fees: Abbott; Genentech; Merck & Co, Inc

Alan R. Tall, MD
Consulting Fees: Amgen; Merck & Co, Inc; Roche

External Reviewer reports the following relationship(s):
William James Howard, MD
Speakers’ Bureau: Abbott; GlaxoSmithKline; Merck & Co, Inc
Advisory Board: Merck & Co, Inc
Consultant: Merck & Co, Inc

Medical Writer reports the following relationship(s):
Valerie Zimmerman, PhD
No relevant financial relationships to disclose.

Endocrine Today® and Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2011 SLACK Incorporated®. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Endocrine Today® and Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Endocrine Today® and Vindico Medical Education. Neither Endocrine Today® , Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.